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Cancer cell tethering and rolling on the vascular wall is facilitated by various selectin: gly-
coprotein interactions which lead to eventual extravasation and metastases.The aberrantly
underglycosylated mucin MUC1 has been shown to both abundantly express selectin
binding moieties (sialyl Lewis x and a) and to consistently expose its core epitope. Flow
cytometry was used to determine MUC1 expression on ZR-75-1 and MCF7 cells, while
immunofluorescence microscopy was used to confirm the aberrant form of MUC1 and
MUC1:ICAM-1 interactions. Each cell line was then perfused through combined E-selectin
and ICAM-1 coated microtubes, as a model of the microvascular endothelium. ZR-75-1
and MCF7 were found to express abundant and low levels of underglycosylated MUC1,
respectively. The rolling/adhesion profiles showed that ZR-75-1 cells, when compared to
MCF7 cells, interact with E-selectin more efficiently resulting in sufficiently slow rolling
velocities to form MUC1:ICAM-1 interactions thereby facilitating firm adhesion. The pur-
pose and novelty of this work is the demonstration of the synergistic adhesion capabilities
of MUC1 in the metastatic adhesion cascade, where the observed differential adhesion
is consistent with the relative metastatic potential of the ZR-75-1 (highly metastatic) and
MCF7 (weakly metastatic) cell lines.
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INTRODUCTION
The mucin family of glycoproteins is traditionally associated with
the protection of the epithelial layer and provides lubrication of
luminal epithelial surfaces. More recently, certain mucins have
been identified as markers for metastatic cancers. Of particular
importance, the mucin MUC1 is overexpressed in numerous can-
cers including breast, ovarian, lung, pancreatic, prostate, gastric,
and colorectal (Zotter et al., 1987; Girling et al., 1989; Ajioka et al.,
1996; Burdick et al., 1997; Retz et al., 1998), where high expres-
sion generally correlates with increased mortality rates (MacLean
et al., 1997; Guddo et al., 1998; Kocer et al., 2004; Duncan et al.,
2007; Tewes et al., 2009). It is then reasonable to hypothesize that
cancer’s adaptation and alteration of MUC1 may play a vital role
in metastatic progression.
Cancer metastasis through the bloodstream is initiated by the
invasion of tumor cells from the primary site into the blood vessel
(Moss and Anderson, 2000). These circulating tumor cells (CTCs)
can then adhere to the endothelial lining, which leads to extrava-
sation and the formation of secondary tumor sites. For CTC
adhesion, cells may first establish transient interactions with the
activated endothelium which facilitates cell tethering and rolling
events (Tremblay et al., 2008; St Hill, 2011; Wirtz et al., 2011).
These types of interactions are produced via selectins, a family
of adhesion molecules expressed by the endothelium, and carbo-
hydrate moieties, such as sialyl Lewis x (sLex) or sialyl Lewis a
(sLea), present on the selectin ligands expressed by CTCs (Borsig
et al., 2002; Varki and Varki, 2007). Once the cell has sufficiently
reduced its rolling velocity, firm adhesion can be acquired through
the interaction between the intracellular cell adhesion molecule
1 (ICAM-1) on the endothelium and integrins on CTCs. This
series of events is commonly referred to as the metastatic adhesion
cascade (Orr et al., 2000).
MUC1 is not only overexpressed in many cancer types but is
also aberrantly underglycosylated. The core structure of the extra-
cellular domain of MUC1 mainly consists of 25–150 repeat units
of 20 identical amino acid sequences rich in serines and threonines
resulting in a length 5–10 times that of most membrane pro-
teins. Normally, these amino acids would be richly O-glycosylated
however aberrant MUC1 has been shown to express shortened
oligosaccharides such as sLex and sLea, and binds efficiently to
E-selectin (Lloyd et al., 1996). Interestingly, high levels of MUC1
carrying sLex/a correlate to poor prognosis in patients with lung
adenocarcinoma (Inata et al., 2007). Aberrant MUC1 also has the
propensity to expose its core epitope due to underglycosylation
where it has become the target of various probes to determine
MUC1 expression (Moore et al., 2004). Furthermore, ICAM-1
has been shown to recognize and bind to the core epitope of
MUC1 (Hayashi et al., 2001). Therefore, CTCs may utilize aberrant
MUC1 to facilitate tethering and rolling due to the increased length
of MUC1 relative to other selectin ligands, and firmly adhere
to the endothelium via ICAM-1 interactions (Regimbald et al.,
1996).
In this study, we investigate the role of MUC1 in breast can-
cer cell adhesion under flow with two cell lines: ZR-75-1 which
is known to have a high metastatic potential, and MCF7 which is
weakly metastatic. The differential adhesion of these two cell lines
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to the endothelium are studied in vitro via micro-renathane tubes
coated with varying ratios of E-selectin and ICAM-1 which repre-
sent a model of metastasis-prone microvasculature (Finzel et al.,
2004). We hypothesize that the underglycosylated form of MUC1
may serve as a ligand for both E-selectin and ICAM-1, which would




Recombinant E-selectin-IgG1 chimera and recombinant ICAM-
1-IgG1 chimera were purchased from R&D systems (Minneapo-
lis, MN, USA). Blotting grade blocker non-fat dry milk was
obtained from Bio-Rad Laboratories (Hercules, CA, USA) and
Protein-G was purchased from EMD Biosciences (San Diego,
CA, USA). FITC mouse anti-human CD227 (clone HMPV),
FITC mouse IgG1 k isotype control, purified mouse anti-human
CD15s (clone CSLEX), APC rat anti-mouse IgM, and FITC goat
anti-mouse IgG/IgM were all purchased from BD Biosciences
(San Jose, CA, USA). FITC mouse anti-human CD44v4 was
obtained from AbD Serote (Germany). FITC and APC anti-
human IgG antibodies were purchased from Invitrogen (Carmar-
illo, CA, USA). Ca2+ and Mg2+ free DPBS (Invitrogen, Camarillo,
CA, USA), calcium carbonate (Sigma Chemical Co., St. Louis,
MO, USA), low endotoxin (1 ng/mg), and essentially globulin-
free Bovine Serum Albumin (Sigma Chemical Co., St. Louis,
MO, USA) were used to prepare flow buffer for cell adhesion
assays.
BREAST CANCER CELL CULTURE
Breast cancer cell lines ZR-75-1 and MCF7 were purchased from
ATCC and maintained in 10% Fetal Bovine Serum (FBS; Cellgro),
1% penicillin-streptomycin (Invitrogen), and RPMI 1640 medium
(ZR-75-1) or eagle’s minimal essential medium with 0.01 mg/mL





FIGURE 1 | (A) Flow cytometry histogram plots of ZR-75-1 and MCF7 labeled
with anti-MUC1 mAb clone HMPV, respectively. (B) Quantification of the MFI
ratio of sample/isotype for both cell types with anti-MUC1 mAb clone SM3
and HMPV, respectively. Student’s t -test was used for statistical analysis and
results from both labeling experiments were found to be significantly different
for ZR-75-1 and MCF7 cells (p≤0.01). (C) Left and middle: confocal
microscopy images of MCF7 and ZR-75-1 labeled with anti-MUC1 mAb (clone
SM3), respectively. Right: strong signal of SM3 anti-MUC1 mAb in the
cytoplasmic region of select ZR-75-1 cells. (D) Left: flow cytometry histogram
of fluorescently tagged ICAM-1 labeling on ZR-75-1 and MCF7 cells. Middle
and right: confocal microscopy images of MCF7 and ZR-75-1 cells labeled
with fluorescently tagged ICAM-1.
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FIGURE 2 | (A,B) Flow cytometry histogram overlays of ZR-75-1 and MCF7
cells labeled with anti-sLex (clone CSLEX) mAb and anti-CD44V4 mAb,
respectively. (C) E-selectin and ICAM-1 fluorescence intensities as
concentration ratios vary during surface preparation. The r 2 values for
E-selectin and ICAM-1 fluorescence intensity trend lines were found to be
0.986 and 0.995, respectively.
FLOW CYTOMETRY
Cells were removed from tissue culture flasks prior to antibody
incubation using an enzyme-free cell dissociation buffer solu-
tion. After washing with 1× DPBS, the cells were resuspended
in 1% BSA in DPBS to a final concentration of approximately
250,000 cells in each sample. Antibodies against MUC1 or appro-
priate isotype controls were added to the cell suspensions and
incubated over ice for 45 min. Specifically, mouse anti-human
MUC1 mAb clone HMPV (reacts with the core peptide of MUC1)
and mouse anti-human MUC1 mAb clone SM3 (recognizes the
underglycosylated form of MUC1) were used in this study. Fol-
lowing incubation, cells were washed twice with 500µL of 1%
BSA to remove any unbound antibody. Flow cytometry samples
were analyzed using a BD Accuri C6 flow cytometer (Ann Arbor,
MI, USA).
SOLUBLE ICAM-1 BINDING ASSAY
Recombinant human ICAM-1-IgG1 chimeric protein (R&D) was
fluorescently tagged with Alexa 647 anti-human IgG antibody and
incubated with ZR-75-1 and MCF7 cells in 1×DPBS with 2% BSA
for 30 min at room temperature. Unbound proteins were washed
off with 1× DPBS twice prior to flow cytometry and confocal
microscopy imaging.
PREPARATION OF COMBINED PROTEIN SURFACES
Micro-renathane tubings (microtubes) with an inner diameter
of 300µm (Braintree Scientific Inc., Braintree, MA, USA) were
cut to lengths of 50 cm. Recombinant human E-selectin-IgG1 and
ICAM-1-IgG1 chimeric proteins were each dissolved in 1× PBS
and mixed in various ratios (E-sel/ICAM-1: 10/0, 7.5/2.5, 5/5,
2.5/7.5, 0/10) to a final protein concentration of 10µg/mL. The
microtube surface was first rinsed with 1× DPBS and then incu-
bated with 10µg/mL of protein-G solution for 1 h, followed by a
2 h incubation with the premixed E-selectin and ICAM-1 protein
solution, then blocked with 5% milk protein in PBS for 1 h. To
evaluate the correlation between incubation concentrations and
surface coverage, FITC conjugated E-selectin and APC conjugated
ICAM-1 were mixed in the ratios described above. Fluorescence
images were taken and analyzed using Image J.1
CELL ADHESION ASSAY
After surface functionalization as described above, microtubes
were secured to the stage of an Olympus IX81 motorized inverted
microscope (Olympus America, Melville, NY, USA). A CCD cam-
era (model no: KP-M1AN, Hitachi, Tokyo, Japan) and a DVD
recorder (model no: DVD-1000MD, Sony Electronics) were used
to record experiments for offline analysis. ZR-75-1 and MCF7
breast cancer cells suspended in flow buffer were perfused through
protein coated microtubes using a syringe pump (KDS 230, IITC
Life Science, Woodland Hills, CA, USA) at a wall shear stress of
1.0 dyne/cm2.
CONFOCAL IMMUNOFLUORESCENCE MICROSCOPY
ZR-75-1 and MCF7 cells were removed from tissue culture flasks,
washed with 1× DPBS, resuspended with 2% BSA in 1× DPBS,
loaded to a pre-assembled cytospin cuvette, and spun at 750 rpm
for 3 min in a Shandon Cytospin 3 centrifuge (Harlow Scientific,
Arlington, MA, USA). Cytospin slides were then dried and fixed
with 4% paraformaldehyde (Electron Microscopy Sciences, Hat-
field, PA, USA) prior to antibody labeling. Indirect surface staining
for MUC1 was performed using mouse anti-human MUC1 mAb
(clone SM3) and Alexa 647 rat anti-mouse mAb as a secondary
antibody. For some cytospin slides, nuclear staining with DAPI
was performed for 10 min at room temperature prior to imaging.
Samples from the soluble ICAM-1 binding assay were deposited
on cytospin slides for imaging. A Zeiss 710 laser scanning confo-
cal microscope at the Cornell University microscopy and imaging
core facility was used to collect images using a 40× objective.
DATA ACQUISITION AND ANALYSIS
“Rolling” cells were defined as those observed to translate in the
direction of flow with an average velocity less than 50% of the
calculated hydrodynamic free stream velocity. The rolling velocity
was calculated by measuring the distance a rolling cell traveled
over a 30 s interval. Videos of rolling cells were taken at three ran-
domly selected locations along the microtube. “Tethering” cells
were defined as cells that were observed to roll intermittently with
fluctuating velocity. The quantity of cells rolling, adherent and
1http://rsbweb.nih.gov/ij/
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FIGURE 3 | Adhesion phenotypes on combined protein surface under
physiological flow of (A) ZR-75-1, (B) MCF7, and (C) SM3 blocked
ZR-75-1 cells. Two-way ANOVA was used for statistical analysis and results
from all conditions were found to be significantly different (p≤0.001).
tethering was determined by recording images at 30 randomly
selected locations along the microtube. All errors are reported as
standard error of the mean, and statistical analyses were performed
using Prism (GraphPad Software, San Diego, CA, USA).
MOLECULAR DYNAMICS
The crystal structure of SM3 bound to the MUC1 core fragment
(1SM3; Dokurno et al., 1998) was obtained from the Protein
Data Bank for use as starting coordinates. The MUC1 frag-
ment was equally extended beyond the SM3:MUC1 interaction
to include all amino acids of one complete tandem repeat unit
(PATSGPAPRTDPASTVGHAP) and the furthest threonine/serine
from SM3 was O-glycosylated with the sLex carbohydrate group.
Using the YASARA2 package of molecular dynamics (MD) pro-
grams, the complex was solvated in a water cube with an initial
2http://yasara.org
FIGURE 4 | Quantification of average number of cells captured on the
surfaces with varying ratios of E-selectin and ICAM-1 for (A) ZR-75-1,
(B) MCF7, and (C) SM3 blocked ZR-75-1 cells. One-way ANOVA was used
for statistical analysis. For all three experiments, results from all conditions
were found to be significantly different with p-values of 0.0008, 0.0093,
and 0.0016 for ZR-75-1, MCF7, and SM3 blocked ZR-75-1, respectively.
**p≤0.01; ***p≤0.001.
length of 100 Å to allow for free protein rotation and neutral-
ized to 0.9% NaCl with physiologically neutral pH (7.4). The
YAMBER3 self-parameterizing force field (Krieger et al., 2004)
was implemented with periodic boundary conditions, the parti-
cle mesh Ewald method for electrostatic interactions (Essmann
et al., 1995) and a recommended 7.86 Å force cutoff for long-
range interactions. Temperature and pressure were held constant
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at 300 K and 1 atm, respectively, while the water box was allowed
to adjust slightly to constrain the water density to 0.997 g/L.
Conformational stresses were then removed via short steepest
descent minimizations and simulated annealing was run until
sufficient convergences were reached. A free dynamics simula-
tion was then run for 10 ns to obtain the final equilibrated
structure.
RESULTS
DIFFERENTIAL MUC1 EXPRESSION ON ZR-75-1 AND MCF7 CELLS AND
THEIR ABILITY TO BIND TO ICAM-1 UNDER STATIC CONDITIONS
MUC1 core peptide expression was measured for both ZR-75-
1 and MCF7 cells via flow cytometry using MUC1 mAb clone
HMPV and found to be significantly higher on ZR-75-1 cells
(Figure 1A). MUC1 mAb clone SM3 was also used to detect
the underglycosylated form of MUC1, which has been identified
as a tumor associated form of MUC1 (Mommers et al., 1999).
Although no significant shift was observed, mean fluorescence
intensity (MFI) of sample/isotype for ZR-75-1 cells was observed
to be five times higher than MCF7 cells (Figure 1B). Furthermore,
confocal microscopy images with MUC1 antibody (SM3) label-
ing showed brighter signals on ZR-75-1 cells (Figure 1C). Strong
homogenous cytoplasmic staining of MUC1 (SM3) was observed
on some ZR-75-1 cells (Figure 1C right) but not on MCF7 cells.
To assay MUC1:ICAM-1 binding under static conditions, human
recombinant ICAM-1 was conjugated with a fluorescently tagged
secondary antibody and incubated with both cell types. Flow
cytometry and confocal microscopy results both showed signif-
icantly stronger binding of ICAM-1 to ZR-75-1 cells compared to
MCF7 cells (Figure 1D).
FIGURE 5 | (A,B) Rolling velocities of ZR-75-1 (untreated and blocked)
and MCF7 cells on combined and E-selectin surfaces with varying
incubation concentrations under flow, respectively. (C) Equilibrated
structure of SM3 (gray) bound to the core epitope of one repeat unit of
MUC1 (red) singly O-glycosylated with sLex (blue) on a threonine
residue. Below is the amino acid sequence of a MUC1 repeat unit
where the bracket indicates the interaction site of SM3 and the blue
arrow indicates the chosen O-glycosylated amino acid. Student’s t -test
and ANOVA were used for statistical analysis. *p≤0.05; ***p≤0.001;
NS, non-significant.
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E-SELECTIN LIGAND AND BINDING MOIETY EXPRESSION ON ZR-75-1
AND MCF7 CELLS
The MFI ratios of sample over isotype control for the E-selectin
binding moiety sLex expression on ZR-75-1 and MCF7 were found
to be 8.43 and 8.56, respectively, via flow cytometry (Figure 2A).
CD44 variant 4 (CD44v4), among the multiple variants of com-
mon E-selectin ligand CD44, has been identified as a major E-
selectin ligand for breast cancer cells (Zen et al., 2008). CD44v4
expression was measured on ZR-75-1 and MCF7 cells via flow
cytometry and no significant difference was observed (Figure 2B).
E-SELECTIN AND ICAM-1 COMBINED SURFACE
The initial layer of protein-G orients the adhesion molecules to
maximally interact with cell surfaces as the cells are perfused
through the tubes. As the E-selectin:ICAM-1 concentration ratios
were increased, the fluorescence intensity of bound E-selectin in
the microtube was found to linearly increase while ICAM-1 flu-
orescence linearly decreased (Figure 2C), verifying the desired
protein concentrations on the microtube surfaces.
MUC1 IS INVOLVED IN THE CANCER ADHESION CASCADE IN
ASSOCIATION WITH E-SELECTIN AND ITS LIGANDS
Figures 3A,B divide the cells that interact with the surface into
three categories: tethering, rolling, and adherent. ZR-75-1 cells
were found to roll quite consistently when E-selectin was present
at any concentration on the surface where there was a slight
decrease in the percent of rolling cells as the E-selectin concen-
tration decreases (Figure 3A). Conversely, the percent of ZR-75-1
tethering cells increased as the E-selectin:ICAM-1 ratio decreased.
Interestingly, adherent ZR-75-1 cells were observed only when
both E-selectin and ICAM-1 exist on the surface and 7.5:2.5
was found to be the optimal ratio of E-selectin:ICAM-1 that
yields the greatest number of adherent cells. However, as the E-
selectin:ICAM-1 ratio decreased so did the percent of adherent
cells. On the other hand, MCF7 rolling and tethering showed little
sensitivity to varying the E-selectin:ICAM-1 ratios where MCF7
tethering cells only slightly increased as the ratio decreased, as
shown in Figure 3B. Most notably, no adherent MCF7 cells were
observed on the surface for any concentration ratio. For both ZR-
75-1 and MCF7 cells, when only ICAM-1 coats the surface no
cells interacted adhesively under flow. Anti-MUC1 mAb (clone
SM3) was found to block the adhesive interactions of ZR-75-1 cells
with the surface, leaving only the tethering and rolling populations
(Figure 3C).
The cell flux for each cell type (Figures 4A–C) shows little sen-
sitivity to the combined surface concentration ratios. However,
overall the ZR-75-1 cell flux is much greater than both MCF7 and
SM3 blocked ZR-75-1 cell fluxes, roughly by a factor of 2. Com-
paring ZR-75-1 to MCF7 and SM3 blocked ZR-75-1 cells, the cell
fluxes inversely correlate with the cell rolling velocities, as shown
in Figures 5A,B, where the ZR-75-1 cell rolling velocities were
found to be slower than MCF7 cell rolling velocities. For exam-
ple, for surfaces coated with only E-selectin, MCF7 cells rolled at
6.74± 0.40µm/s whereas ZR-75-1 cells rolled at 1.93± 0.06µm/s.
SM3 blockade was found to cause an increase in rolling velocity
to approximately 4µm/s, significantly faster than untreated cells.
A structure of SM3 bound to the underglycosylated core epitope
of MUC1 is depicted in Figure 5C, where SM3 not only blocks
FIGURE 6 | Proposed mechanism by which MUC1 can act as a ligand for E-selectin, initiating tethering, and rolling events of CTCs on the
endothelium, and subsequently serve as an ICAM-1 ligand, mediating firm adhesion of CTCs.
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ICAM-1 interactions, but is sufficiently bulky compared to sLex
to inhibit some amount of E-selectin interactions as well. Unlike
cell flux, both ZR-75-1 (untreated and blocked) and MCF7 cell
rolling velocities were sensitive to the E-selectin concentration
where cell rolling velocities increased as the E-selectin concen-
tration decreased (Figures 5A,B). Furthermore, the MCF7 cell
rolling velocity at the lowest E-selectin concentration was double
that of the cell rolling velocity at the highest E-selectin concentra-
tion which shows a greater sensitivity to E-selectin compared to
ZR-75-1 cells.
DISCUSSION
The detection and enumeration of CTCs holds great poten-
tial in breast, colorectal, and prostate cancer prognosis, yet the
basic biophysics of how these CTCs interact with the endothe-
lium is not fully understood. Similar to leukocyte recruitment to
the endothelium, CTC tethering and rolling on the blood ves-
sel wall under hydrodynamic shear stress are also mediated by
the selectin family of adhesion molecules (Geng et al., 2012).
After stable rolling on the endothelium, leukocytes can firmly
adhere to the inflamed endothelium via leukocyte beta-2 inte-
grin (Mac-1, LFA-1): ICAM-1 binding (Diamond et al., 1990;
Ding et al., 1999; King, 2006). Similarly for epithelial-type CTCs,
tumor associated MUC1 may play the role of beta-2 integrins
on leukocytes by binding ICAM-1 to enable firm adhesion and
initiate subsequent events in the metastatic cascade (Rahn et al.,
2005).
Tumor associated MUC1 on breast cancer cells was first identi-
fied as a novel adhesion ligand for endothelial ICAM-1 by Regim-
bald et al. (1996) via static adhesion assays between MCF7 cells
and stimulated HUVEC cells as well as immobilized recombinant
ICAM-1. MCF7 cells do not express common ICAM-1 ligands,
such as LFA-1, Mac-1, or CD43. However under static condi-
tions, MUC1 was found to interact with ICAM-1, which could
mediate firm adhesion of CTCs to the inflamed endothelium.
In contrast, we characterized the adhesive role of tumor associ-
ated MUC1 under hydrodynamic shear stress by perfusing both
ZR-75-1 (which overexpresses MUC1) and MCF7 cells through
functionalized microtubes, more representative of the blood ves-
sel microenvironment. Furthermore, the inflamed endothelium
was simulated by immobilizing both E-selectin and ICAM-1
with varying ratios on the microtube surface, creating a more
physiologically relevant and controllable environment to study
the adhesion events of circulating ZR-75-1 and MCF7 cells under
flow.
ZR-75-1 cells show a much greater expression of underglycosy-
lated MUC1 compared to MCF7 cells, which significantly affects
their adhesion behavior when perfused through the combined
surface microtubes. Interestingly, although ZR-75-1 and MCF7
cells have similar expression levels of sLex, one of the E-selectin
binding moieties, ZR-75-1 cells roll on the combined protein
surface at a significantly slower rolling velocity, indicating that
ZR-75-1 cells establish stronger interactions with E-selectin. Recall
that underglycosylated forms of MUC1 also contain shortened
oligosaccharides where sLex is one of the most common carbohy-
drates of aberrant MUC1 (Burdick et al., 1997). Therefore MUC1,
when appropriately decorated with sLex in its underglycosylated
form, is expected to extend further from the cell surface compared
to other selectin ligands due to its size and is perhaps more able to
interact with E-selectin to efficiently mediate tethering and rolling
events. The greater rolling velocities of ZR-75-1 cells blocked with
SM3 also suggests MUC1 is an important E-selectin ligand because
SM3 could inhibit some amount of E-selectin:MUC1 interac-
tions due to the size of SM3 compared to sLex (Figure 5C). As
a result of the slower rolling velocity and greater MUC1 expres-
sion, only ZR-75-1 cells firmly adhered to the combined surface,
where firm adhesion is facilitated by MUC1:ICAM-1 interactions.
In our study, the observation of firmly adhered cells to the com-
bined surface under shear stress is consistent with the metastatic
potential of the ZR-75-1 cell line (highly metastatic) and the MCF7
cell line (weakly metastatic).
In conclusion, we propose a mechanism by which MUC1 can
act as a ligand for E-selectin, initiating tethering and rolling events
of CTCs on the endothelium, and subsequently serve as an ICAM-
1 ligand, mediating firm adhesion of CTCs (Figure 6). The syn-
ergistic effect of MUC1:E-selectin and MUC1:ICAM-1 may play
an important role in breast cancer metastasis through the blood-
stream where underglycosylated MUC1 can significantly slow the
rolling velocity of CTCs thereby allowing for more frequent occur-
rence of firm adhesion events and subsequent extravasation. In
summary, our results provide new insights into the roles of MUC1
in the metastatic adhesion cascade and suggests future exami-
nation into clinical aspects where the underglycosylated form of
MUC1 can be targeted since aberrantly underglycosylated MUC1
expression is highly correlated to poor prognosis in breast and
colon cancer patients.
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